Welcome to our dedicated page for Biovie news (Ticker: BIVI), a resource for investors and traders seeking the latest updates and insights on Biovie stock.
BioVie Inc. (NASDAQ: BIVI) generates news primarily through its clinical development programs in neurological and neurodegenerative disorders and advanced liver disease. Company announcements frequently highlight progress with its lead candidate bezisterim (NE3107) in Alzheimer’s disease, Parkinson’s disease and long COVID, as well as developments in its BIV201 program for complications of advanced liver cirrhosis.
Recent news releases have described milestones in the SUNRISE-PD Phase 2 trial in early Parkinson’s disease, including the use of a hybrid, decentralized design that allows participants to complete visits at home or in clinics, and the completion of enrollment in that study. BioVie also issues updates on scientific presentations at international conferences, where it has discussed bezisterim’s potential effects on biological aging markers, DNA methylation patterns, inflammatory gene expression, and metabolic and inflammatory biomarkers in Alzheimer’s disease.
In long COVID, BioVie’s news flow includes coverage of the ADDRESS-LC Phase 2 trial, which is enrolling adults with fatigue and cognitive impairment associated with long COVID and is fully funded by a U.S. Department of Defense grant. Press releases describe the trial’s enrichment strategy, objective cognitive endpoints, and the rationale for targeting neuroinflammation and insulin resistance in this condition.
BioVie also reports on capital markets and corporate events, such as underwritten public offerings of units consisting of common stock (or pre-funded warrants) and warrants, the listing of its warrants under the symbol BIVIW, and investor webinars featuring management discussing clinical data and program updates. Regulatory and governance news, including reverse stock split implementation, proxy statements, and board appointments, is disclosed through SEC filings and related communications.
Investors and observers following BIVI news can expect updates on clinical trial enrollment and topline data timing, scientific presentations, financing transactions, and corporate governance actions, all of which are documented in the company’s press releases and regulatory filings.
BioVie Inc. (NASDAQ:BIVI) is participating in B. Riley Securities’ Liver Disease Therapeutics Day 2020 on October 29, 2020, at 11:00 a.m. ET. Company executives, including Chairman & CEO Terren Peizer, will discuss the clinical development program and revenue opportunities for their Orphan Drug candidate BIV201. This therapy aims to treat ascites from advanced liver cirrhosis, with a Phase 2 trial expected to commence soon. BIV201 offers unique delivery advantages and is poised to fill a critical gap in the market, as no FDA-approved treatments currently exist for ascites.
BioVie Inc. (NASDAQ:BIVI), a clinical-stage company, announced that President & COO Jonathan Adams will present at the Oppenheimer Fall Healthcare Life Sciences & Medtech Summit on September 21, 2020, at 1:40 p.m. ET. The company is developing BIV201, an innovative therapy for ascites due to advanced liver cirrhosis. This orphan drug candidate aims to simplify treatment with a novel prefilled syringe system. Notably, BIV201 addresses a market gap as no FDA-approved treatments for ascites exist, with the potential for future indications in hepatorenal syndrome.
BioVie Inc. (NASDAQ:BIVI) announced a public offering of 1,565,200 shares at $10.00 per share, aiming to raise $15.65 million before costs. Additionally, underwriters have a 45-day option for 234,780 more shares. The offering is set to close on September 22, 2020. This funding will support clinical trials for BIV201, its candidate for liver disease and cover general corporate needs. BioVie’s stock will debut on Nasdaq on September 18, 2020.